At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, DOUBLE-BLIND TRIAL EVALUATING THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS GIVEN WITH ROUTINE PEDIATRIC VACCINATION IN TAIWAN
In Brief
A Phase 3 clinical trial evaluating 13-valent pneumococcal conjugate vaccine (13vPnC) and 7-valent pneumococcal conjugate vaccine (7vPnC) for Vaccines and Pneumococcal Conjugate Vaccine. Completed, enrolled 168 participants across 2 sites.
Detailed Summary
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC), relative to a 7-valent pneumococcal conjugate vaccine (7vPnC) when given concomitantly with routine vaccines in Taiwan.
Study Details
Timeline
Interventions
13vPnC is given via intramuscular injection at approximately 2, 4, 6, and 15 months of age.
7vPnC is given via intramuscular injection at approximately 2, 4, 6, and 15 months of age.